US Patent Issued to Cura Therapeutics on March 25 for "Multi-functional and multi-valent interleukin-TGF-beta receptor fusion polypeptides" (Canadian Inventor)

ALEXANDRIA, Va., March 26 -- United States Patent no. 12,258,383, issued on March 25, was assigned to Cura Therapeutics Inc. (Montreal).

"Multi-functional and multi-valent interleukin-TGF-beta receptor fusion polypeptides" was invented by Claudia Ania Penafuerte Diaz (Montreal).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are multi-functional and multi-valent fusion polypeptides comprising an interleukin polypeptide and two or more TGFBeta ligand-binding polypeptides. The compositions and methods provided herein are useful in the application of preventing tumorigenesis and treating cancer."

The patent was filed on June 30, 2022, under Application No. 17/810,128.

*For further information, includin...